1. Home
  2. CTKB

as of 11-19-2026 3:59pm EST

$6.32
+$0.52
+8.87%
Stocks Health Care Biotechnology: Electromedical & Electrotherapeutic Apparatus Nasdaq

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.

Founded: 1990 Country:
United States
United States
Employees: N/A City: FREMONT
Market Cap: 777.3M IPO Year: 2021
Target Price: $6.50 AVG Volume (30 days): 1.1M
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -0.09 EPS Growth: -550.00
52 Week Low/High: $3.31 - $6.33 Next Earning Date: 11-04-2026
Revenue: $193,015,000 Revenue Growth: 17.67%
Revenue Growth (this year): 3.83% Revenue Growth (next year): 6.48%
P/E Ratio: -64.50 Index:
Free Cash Flow: -8770000.0 FCF Growth: N/A

Earnings Transcripts

SEC 8-K filings with transcript text

View All
2026
Q3

Q3 2026 Earnings

8-K SELL

Nov 4, 2026 · 97% conf.

AI Prediction SELL

1D

-6.40%

$5.50

Act: -6.80%

5D

-12.84%

$5.13

20D

-14.16%

$5.05

Price: $5.88 Prob +5D: 1% AUC: 1.000
0001193125-26-447300

EX-99.1

2 d186499dex991.htm

EX-99.1

EX-99.1

Exhibit 99.1

Cytek Biosciences Reports Third Quarter 2026 Financial Results

FREMONT, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2026.

Recent Highlights

•

Total revenue for the third quarter of 2026 was $53.2 million, representing a 2% increase compared to the third quarter of 2025

•

Total recurring revenue, comprised of service and reagent revenues, reached $19.1 million in the third quarter. On a trailing-12-month basis, recurring revenue represented 36% of total revenue, up from 33% on a trailing-12-month basis as of the third quarter of 2025

•

Delivered GAAP gross margin of 59% representing a 590 basis point improvement compared to the third quarter of 2025

•

Expanded to a total installed base of 4,073 Cytek instruments, adding 140 units in the third quarter of 2026

•

Maintaining the midpoint of full year 2026 total revenue guidance and narrowing the range to $208 million to $211 million

“We delivered another solid third quarter, with growth led by the U.S., where revenue grew 12%, and double-digit growth in our service business,” said Wenbin Jiang, CEO of Cytek Biosciences. “Demand for our high-end instruments remained strong, with high-end Full Spectrum Profiling instrument revenue up 11% and Aurora Evo placements nearly doubling year over year. We also expanded gross margin by nearly 600 basis points. Looking ahead, we are reiterating the midpoint of our full-year revenue guidance and expect a strong finish to the year. We are well positioned to keep gaining market share, with our new product launches continuing to strengthen our technology leadership.”

Third Quarter 2026 Financial Results

Total revenue for the third quarter of 2026 was $53.2 million, a 2% increase compared to the third quarter of 2025. The increase in revenue was driven by growth in the U.S., led by strong demand for high-end instruments and continued growth in service.

GAAP gross profit was $31.2 million for the third quarter of 2026, a 13% increase compared to the third quarter of 2025. GAAP gross profit margin was 59% in the third quarter of 2026 compared to 53% in the third quarter of 2025. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 61% in the third quarter of 2026 compared to 55% in the third quarter of 2025. This represents the best GAAP and adjusted gross margin for a third quarter since 2023.

Operating expenses were $39.6 million for the third quarter of 2026, an 8% increase compared to the third quarter of 2025, primarily due to higher general and administrative expenses.

Research and development expenses were $9.4 million for the third quarter of 2026, a 4% increase compared to the third quarter of 2025. The increase in expenses for the three months ended September 30, 2026 was primarily driven by higher personnel costs, offset by lower engineering expenses.

Sales and marketing expenses were $11.9 million for the third quarter of 2026, a 2% increase compared to the third quarter of 2025.

General and administrative expenses were $18.4 million for the third quarter of 2026, a 14% increase compared to the third quarter of 2025, primarily due to higher litigation-related expenses, partially offset by lower compensation and severance expenses and the non-recurrence of a write-off of deferred offering costs in the prior-year period.

Loss from operations in the third quarter of 2026 was $8.4 million, compared to loss from operations of $9.2 million in the third quarter of 2025. Net loss in the third quarter of 2026 was $6.1 million, compared to a net loss of $5.5 million in the third quarter of 2025.

Adjusted EBITDA was $0.7 million for the third quarter of 2026, compared to adjusted EBITDA of $2.5 million in the third quarter of 2025, after adjusting for stock-based compensation expense, foreign currency exchange impacts and, in the prior-year period, a non-recurring write-off of deferred at-the-market (“ATM”) facility offering costs.

Cash, cash equivalents, restricted cash and marketable securities totaled $256.3 million as of September 30, 2026, compared to $262.0 million as of June 30, 2026, a decrease of $5.7 million.

2026 Outlook

Cytek Biosciences is maintaining the midpoint of its revenue outlook for the full year 2026 and narrowing the range to $208 million to $211 million, assuming no change in current foreign currency exchange rates.

Corporate Update

On August 21, 2026, Cytek Biosciences announced that a jury in the U.S. District Court for the District of Delaware found in Cytek’s favor on three of the four asserted claims, finding both non-infringement and invalidity for each of those three claims. On the fourth claim, the jury found no literal infringement but di

2026
Q2

Q2 2026 Earnings

8-K SELL

Aug 5, 2026 · 100% conf.

AI Prediction SELL

1D

-6.60%

$3.90

Act: -0.48%

5D

-13.00%

$3.64

Act: +14.35%

20D

-14.34%

$3.58

Price: $4.18 Prob +5D: 0% AUC: 1.000
0001193125-26-335212

Transcript text not available. View on SEC.gov →

2026
Q1

Q1 2026 Earnings

8-K SELL

May 7, 2026 · 100% conf.

AI Prediction SELL

1D

-6.58%

$4.60

Act: -6.81%

5D

-11.44%

$4.36

Act: -31.81%

20D

-14.13%

$4.22

Act: -16.87%

Price: $4.92 Prob +5D: 0% AUC: 1.000
0001193125-26-211948

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784723432.75b0687

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.

Share on Social Networks: